The progression of microbiome therapeutics for the management of gastrointestinal diseases and beyond
File(s)FInal Gastro Rev clean 5-2.docx (346.58 KB)
Accepted version
Author(s)
Allegretti, Jessica R
Khanna, Sahil
Mullish, Benjamin H
Feuerstadt, Paul
Type
Journal Article
Abstract
There has been an increased ability to investigate human microbiota through next-generation sequencing and functional assessment. This advancement has rapidly expanded our ability to study and manipulate the gastrointestinal microbiome to mitigate disease. Fecal microbiota transplantation, a therapy that broadly transfers the entire intestinal ecosystem, has been explored as a potential therapeutic in a variety of gastrointestinal, hepatic, and extraintestinal conditions. The field, however, continues to evolve, with a movement toward precision microbiome therapeutics individualizing care for various disorders. This review will describe the use of fecal microbiota transplantation, microbiota restoration, and precision microbiome therapeutics focusing on gastrointestinal and hepatic diseases.
Date Issued
2024-10-01
Date Acceptance
2024-05-09
Citation
Gastroenterology, 2024, 167 (5), pp.885-902
ISSN
0016-5085
Publisher
Elsevier
Start Page
885
End Page
902
Journal / Book Title
Gastroenterology
Volume
167
Issue
5
Copyright Statement
Copyright © 2024 by the AGA Institute. This is the author’s accepted manuscript made available under a CC-BY licence in accordance with Imperial’s Research Publications Open Access policy (www.imperial.ac.uk/oa-policy).
License URL
Identifier
https://www.sciencedirect.com/science/article/pii/S0016508524049151
Publication Status
Published
Date Publish Online
2024-05-14